Department of Geriatric Medicine and Neurology, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
Department of Neurology, West China Hospital, Sichuan University, Chengdu, China.
Audiol Neurootol. 2021;26(6):479-486. doi: 10.1159/000518615. Epub 2021 Sep 28.
OBJECTIVES: This study was conducted to explore the effectiveness of hyperbaric oxygen (HBO) in the treatment of idiopathic sudden sensorineural hearing loss (ISSNHL) and recommend the appropriate course of treatment. METHODS: 102 patients (105 diseased ears) with ISSNHL were recruited from the Department of Neurology and Otorhinolaryngology, West China Fourth Hospital, Sichuan University, between January 2018 and September 2020. Of them, 45 patients (group A) received intravenous steroid (IVS), and the remaining patients (group B) received IVS and HBO therapy (HBOT). Pure-tone audiometry (PTA) was performed twice at baseline and 10 days after treatment. Patients in group B were subdivided into group 1 (≤10 sessions) and group 2 (>11 sessions) to verify the correlation between the efficacy and course of HBOT, at the follow-up endpoint, the PTA was performed again. The multivariate logistical regression model was used to analyze the related factors of prognosis. RESULTS: Compared with the control group, significantly larger hearing gains and better hearing recovery rate were observed in the IVS + HBOT group (p < 0.05). The time of treatment and course of HBOT were significantly correlated with the hearing threshold after treatment (p < 0.05) and had no significant relationship with tinnitus and age (p > 0.05). CONCLUSION: HBOT + IVS is an effective method for ISSNHL, especially for the recovery of low-frequency hearing and initial hearing levels of severe and profound. Tinnitus is the most common concomitant symptom of ISSNHL, and prolonging the course of HBOT did not significantly improve it. Initiating HBOT within 7 days for 10-25 sessions of treatment was more beneficial.
目的:本研究旨在探讨高压氧(HBO)治疗特发性突发性聋(ISSNHL)的疗效,并推荐合适的治疗疗程。
方法:2018 年 1 月至 2020 年 9 月,我们从四川大学华西第四医院神经内科和耳鼻喉科招募了 102 例(105 耳)ISSNHL 患者。其中 45 例患者(A 组)接受静脉类固醇(IVS)治疗,其余患者(B 组)接受 IVS 和 HBO 治疗(HBOT)。在基线和治疗后 10 天进行两次纯音听阈测试(PTA)。B 组患者进一步分为组 1(≤10 次)和组 2(>11 次),以验证 HBOT 疗效与疗程的相关性,在随访终点再次进行 PTA。采用多变量逻辑回归模型分析预后的相关因素。
结果:与对照组相比,IVS + HBOT 组的听力增益和听力恢复率显著更大(p<0.05)。治疗时间和 HBOT 疗程与治疗后听力阈值显著相关(p<0.05),与耳鸣和年龄无显著关系(p>0.05)。
结论:HBOT + IVS 是 ISSNHL 的有效治疗方法,尤其是对低频听力和重度及极重度初始听力水平的恢复。耳鸣是 ISSNHL 最常见的伴随症状,延长 HBOT 疗程并不能显著改善其症状。在发病后 7 天内开始治疗,10-25 次治疗更为有利。
Eur Arch Otorhinolaryngol. 2016-9
Otolaryngol Head Neck Surg. 2015-10
Eur Arch Otorhinolaryngol. 2010-7-14
Healthcare (Basel). 2025-1-13
Med Gas Res. 2024-12-1
Otolaryngol Clin North Am. 2022-10